# SRTD Biotech raises €31.5 million for targeted RNA therapies

_Published Monday, November 9, 2026 at 9:06 AM EST · Capital · Latest · Tier 2 — Notable_

![SRTD Biotech raises €31.5 million for targeted RNA therapies — Primary](https://www.eu-startups.com/wp-content/uploads/2026/11/Untitled-Design-2026-11-09T180756.137.jpg)

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.

The Jülich-based company says its technology uses RNA markers inside cells to activate therapeutic payloads in target cells while limiting exposure in healthy tissue. Its platform also combines delivery technology with synthetic biology and AI-driven RNA design.

Following the financing, Matthias Alder was appointed chief executive. He said the proceeds would support development of the company's RNA therapeutics; safer and more effective treatments remain its development goal.

## Sources

- [EU-Startups](https://www.eu-startups.com/2026/11/julich-based-srtd-biotech-secures-e31-5-million-to-develop-precision-mrna-therapies-targeting-diseased-cells/)

---
Canonical: https://techandbusiness.org/newswire/CDi5V_jhtVOrw30dHif7oz
Published: 2026-11-09T14:06:32.680Z
Story chronology: 2026-11-09T12:43:19.000Z
Retrieved: 2026-11-09T16:08:59.502Z
Publisher: Tech & Business (techandbusiness.org)